Merck 4Q Revenues: $10.4 billion (+3%) 4Q Loss: $872 million (loss of $594 million 4Q16)   FY Revenues:$40.1 billion (+1%) FY Earnings: $2.6 billion (-34%) Comments: Pharmaceutical sales increased 4% to $9.3 billion in the quarter, driven primarily by significant growth of KEYTRUDA, up 166% to $1.3 billion, reflecting continued launches with new indications globally. Sales of GARDASIL were $633 million, up 17% in the quarter and include approximately $115 million for the partial replenishme...